Bolt Biotherapeutics, Inc. (BOLT)

Market Cap	10.09M -28.9%
Revenue (ttm)	6.50M +78.6%
Net Income	-29.58M
EPS	-16.34
Shares Out	1.92M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,737
Open	5.20
Previous Close	5.29
Day's Range	5.13 - 5.30
52-Week Range	3.91 - 7.35
Beta	1.10
Analysts	Buy
Price Target	41.00 (+680.73%)
Earnings Date	May 12, 2026

About BOLT

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company’s pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembr...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 5, 2021
• Employees: 23
• Stock Exchange: NASDAQ
• Ticker Symbol: BOLT
• Website: https://www.boltbio.com

Financial Performance

In 2025, Bolt Biotherapeutics's revenue was $7.70 million, an increase of 0.07% compared to the previous year's $7.69 million. Losses were -$33.38 million, -47.12% less than in 2024.

Analyst Summary

According to 4 analysts, the average rating for BOLT stock is "Buy." The 12-month stock price target is $41.0, which is an increase of 680.73% from the latest price.

Price Target

$41.0

(680.73% upside)

Analyst Consensus: Buy